

**An Important Message from
The Texas Health and Human Services Commission (HHSC)**

**Clinical Prior Authorization Revisions for Emflaza, Agamree, and
Sogroya Implement this July**

Background:

On April 24, 2026, the Texas Drug Utilization Review (DUR) Board approved proposed revisions to the Duchenne Muscular Dystrophy Agents clinical prior authorization criteria. On June 11, 2026, HHSC updated the Sogroya criteria in the Growth Hormone clinical prior authorization criteria guide.

Key Details:

The DUR Board approved removing the prednisone step requirement from the Emflaza and Agamree clinical prior authorization criteria. VDP published the updated criteria document under the revised category name, Duchenne Muscular Dystrophy Agents. This clinical prior authorization is optional for MCOs, but MCOs that implemented them must revise their [Agamree](#) and Emflaza processes to align with the DUR Board approved changes by **July 6, 2026**.

VDP also updated the criteria for Sogroya (somapacitan-beco) in the Growth Hormones clinical prior authorization criteria guide. This update allows claim approval for patients aged 2-and-a-half years or older with short stature born small for gestational age and with no catch-up growth by 2 years of age, growth failure associated with Noonan syndrome, and idiopathic short stature. MCOs have until **July 14, 2026**, to implement this process.

As a reminder, MCO specific clinical criteria must not be more stringent than the HHSC-approved standards. MCOs should consult the [Clinical Prior Authorizations for Managed Care](#) section for further details.

Action:

MCOs must make revisions to their systems for any implemented clinical prior authorization as follows:

- Duchenne Muscular Dystrophy Agents by July 6, 2026
- Growth Hormone by July 14, 2026

Resources:

- [Duchenne Muscular Dystrophy clinical prior authorization criteria guide \(PDF\)](#)
- [Growth Hormone clinical prior authorization criteria guide \(PDF\)](#)

Questions?

If you have questions, please contact UnitedHealthcare Customer Service at 888-887-9003, 8 a.m.–6 p.m. CT, Monday–Friday.